Insights

Imugene (ASX:IMU) share price jumps 6% on Japanese patent news

Imugene shares are climbing higher in afternoon trade today…
The post Imugene (ASX:IMU) share price jumps 6% on Japanese patent news appeared first on The Motley Fool Australia. –

The Imugene Ltd (ASX: IMU) share price is edging higher in afternoon trade on Wednesday and now trades at 48 cents apiece.

That’s a 5.5% gain on the day, well ahead of the S&P/ASX 200 Health Care index which has climbed 0.45%.

Imugene shares are on the move after the company announced a key patent update regarding one of its immunotherapies.

Here’s what we know.

Imugene share price jumps after patent approval

Imugene advised it was granted patent approval from the Japanese Patent Office for protection over its HER-Vaxx immunotherapy.

The HER-Vaxx regime is “currently in development” for a type of gastric malignancy known as HER2 positive gastric cancer.

As a result of the approval, the patent grants protection over “method of composition and method of use” for the biopharma company’s label.

This is the patent you’d want when applying for one – it covers the design and use of the product. That means Imugene’s rivals can’t copy how HER-Vaxx is made or copy its mechanism of action.

What’s more, the patent grants protection over the company’s technology until 2036, giving Imugene plenty of time to get things right.

The company’s announcement also notes that “approximately 75% of all gastric cancer diagnoses are in Asia”. It’s an alarming statistic compounded by the fact Japan has “the thirst highest incidence of gastric cancer worldwide”.

Of these cases, “approximately one in five” is diagnosed as HER2 positive which means the market for HER-Vaxx is large. The potential to make a meaningful difference is equally as large.

What did management say?

Speaking on the announcement, Imugene’s CEO Leslie Chong said:

Attaining the key Japanese patent is an important milestone. This adds extra value to Imugene’s portfolio of B-cell immunotherapies and this will protect them in one of the world’s largest HER2 positive gastric cancer markets until 2036.

Imugene share price snapshot

The Imugene share price has been a major outperformer this year to date, posting a return of 380% since January 1.

In the last month alone, Imugene shares have climbed a further 68% into the green.

This extends the return over the previous 12 months to 943%, well ahead of the broad index’s gain of around 25% over the past year.

The post Imugene (ASX:IMU) share price jumps 6% on Japanese patent news appeared first on The Motley Fool Australia.

Should you invest $1,000 in Imugene right now?

Before you consider Imugene, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Imugene wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

These 3 ASX Healthcare shares are running hot today

Which ASX shares are leading the way on the ASX 300?

Here’s why the Imugene (ASX:IMU) share price is up 6% so far this week
Which ASX 300 shares are making the biggest moves on Tuesday?

Why the Imugene (ASX:IMU) share price is tumbling 7%

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!